Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of the patients with comparison between patients with/without persistent arthritis at one year

From: The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis

  All patients
(n = 376)
Persistent disease
(N = 174)
Self-limiting disease
(N = 202)
P*
   Persistent synovitis
(with or without DMARD)
(N = 122)
DMARD prescribed
(without persistent synovitis)$
(N = 52)
  
Female gendera 218 (58.0) 78 (63.9) 32 (61.5) 108 (53.5) 0.06
Age, yearsb 46.3 (14.8) 49.0 (14.9) 45.6 (17.1) 44.9 (14.0) 0.04
Arthritis duration, daysc 32 (10 to 64) 50 (21 to 69) 59 (27 to 76) 21 (7 to 49) <0.001
SJC (0 to 68)c 2 (1 to 5) 4 (1 to 9) 4 (2 to 8) 1 (1 to 3) <0.001
TJC (0 to 28)c 1 (1 to 3) 2 (1 to 6) 2 (1 to 5) 1(0 to 2) <0.001
ESR, mm/hc 24 (11 to 46) 27 (10 to 50) 32 (17 to 51) 19 (10 to 38) 0.005
CRP, mg/lc 15.0 (5.0 to 36.4) 15 (5 to 35) 18 (9 to 45) 14.0 (3.5 to 36.2) 0.16
IgM RF level, units/mlc 4 (1 to 10) 6 (2 to 40) 6 (2 to 30) 3 (1 to 7) <0.001
IgM RF positivea 59 (15.7) 36 (29.5) 13 (25.0) 10 (5.0) <0.001
Anti-CCP2 level, units/mlc 3 (2 to 6) 4 (2 to 83) 4 (2 to 25) 2 (2 to 4) <0.001
Anti-CCP2 positivea 62 (16.5) 39 (32.0) 13 (25.0) 10 (5.0) <0.001
Assessor's global VAS, mmb 35.8 (20.7) 39.5 (21.8) 44.7 (23.0) 31.3 (18.2) <0.001
Patient's global VAS, mmb 53.8 (24.0) 57.4 (21.9) 59.5 (26.1) 50.2 (24.1) 0.001
Small joint arthritisa 173 (46.0) 73 (59.8) 33 (63.5) 67 (33.2) <0.001
Morning stiffness>1 houra 195 (51.9)§ 70 (57.9) 31 (60.8) 101 (58.0) 0.04
DAS28b 4.05 (1.32) 4.47 (1.35) 4.61 (1.36) 3.65 (1.15) <0.001
HAQ (0-3)b 0.89 (0.67) 0.98 (0.64) 1.07 (0.80) 0.78 (0.63) 0.001
Monoarthritisa 154 (41.0) 37 (30.3) 12 (23.1) 105 (52.0) <0.001
   -of the kneea 80 (51.9) 20 (54.1) 6 (50.0) 54 (51.4) 0.85
Fulfilment of 1987 ACR criteriaa† 70 (18.6) 37 (30.3) 16 (30.8) 17 (8.4) <0.001
  1. ACR: American College of Rheumatology; anti-CCP2: 2nd generation anti-citrullinated peptide antibody; CRP: C-reactive protein; DAS: Disease Activity Score; ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; RF: rheumatoid factor; SJC: swollen joint count; TJC: tender joint count; VAS: visual analogue scale; small joint arthritis, joint swelling in PIP-, MCP- or MTP joint(s).
  2. $No statistical differences between the persistent arthritis group and DMARD group for any of the baseline variables were found.
  3. *Comparing persistent disease group with self-limiting disease group.aCount (%).bMean (standard deviation).cMedian (inter-quartile range).§N = 369.Modified from the 1987 ARA criteria according to available data (excluding criteria on erosive disease and duration of symptoms).